NEW YORK, June 23, 2016 /PRNewswire/ --
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Aduro BioTech Inc. (NASDAQ: ADRO). Learn more about these stocks by accessing their free trade alerts at:
Dublin, Ireland headquartered biopharmaceutical Company, Alkermes PLC's stock advanced 2.84% to close the day at $43.04 with a total volume of 795,144 shares traded. The Company's shares have gained 0.37% in the last one month and 39.02% in the previous three months. The stock is trading 3.44% above its 50-day moving average. Additionally, Alkermes' stock has a Relative Strength Index (RSI) of 49.90. Sign up and read the free notes on ALKS at:
Waltham, Massachusetts headquartered specialty pharmaceutical Company, AMAG Pharmaceuticals Inc.'s stock finished Wednesday's session 3.51% higher at $24.46 with a total volume of 1.01 million shares traded. Over the last one month and the previous three months, the Company's shares have surged 29.83% and 18.28%, respectively. The stock is trading above its 50-day moving average by 8.26%. AMAG Pharmaceuticals' stock has an RSI of 60.77. The complimentary notes on AMAG can be downloaded in PDF format at:
On Wednesday, shares in IDEXX Laboratories Inc. ended the session 0.42% higher at $90.04 with a total volume of 412,217 shares traded. Shares of the Company traded at a PE ratio of 43.43. The Company's shares have gained 2.18% in the last one month, 19.32% in the previous three months, and 36.90% in the past one year. The stock is trading 4.51% above its 50-day moving average and 18.62% above its 200-day moving average. Moreover, shares of IDEXX Laboratories which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide, have an RSI of 60.30. Register for free on Stock-Callers.com and access the latest research on IDXX at:
On Wednesday, shares in Berkeley, California-based clinical-stage immunotherapy Company, Aduro BioTech Inc., recorded a trading volume of 572,092 shares, which was higher than their three months average volume of 528,810 shares. The stock ended the day 7.00% lower at $10.23. The stock is trading below its 50-day moving average by 15.58%. Furthermore, shares of Aduro BioTech have an RSI of 33.07. Get free access to your trade alert on ADRO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA